-
A NEW QUICK AND CHEAP
METHOD FOR THE DETECTION
OF GLAUCOMAThe Danish retinography analysis software Retinalyze System A / S (Ltd.)
leader in visual "screenings", presents a new and accessible ocular
analysis method, a glaucoma detection service based on artificial intelligence
called Retinalyze Glaucoma.more information -
RetinaLyzePrevents blindness caused
by diabetes and macular
degeneration -
Scientifacally proved with
96% certainty of results

DIABETIC RETINOPHATY
Detection in a premature state is vital since with a quick action and simple treatment can prevent the development of visual disability and blindness.

MACULAR DEGENERATION
RetinaLyze checks efficiently and quickly possible changes in the retina caused by diabetic retinopathy (DR) and / or the Macular Degeneration with age (DMAE).

EARLY DIAGNOSTIC
RetinaLyze offers concrete and effective results in just 30 seconds. If lesions are detected, the final diagnosis should always be performed by an ophthalmologist.

PROFESSIONALS
RetinaLyze team is composed by different people, all very passionate about their area of specialty. Please contact us at any time.
RetinaLyze’s mission is to prevent vision loss. Diabetes is a problem that is advancing around the world and it is estimated that by 2020 there will be over 300 million registered diabetic (type 1 or 2). In addition, by then it is estimated that the number of unregistered diabetics will exceed 250 million. One of the most feared consequences of diabetes is diabetic retinal pathology since it may lead to blindness. It is therefore essential to make an early diagnosis, which is possible through RetinaLyze.
Choose RetinaLyze
96% Percentage of certitude both negative and positive. As reliable as any analysis done with conventional methods but in only 30 seconds.

Facilitates visual inspection to prevent dramatic consequences caused by delayed treatment of retinal lesions.
Percentage of certitude of 96%
Easy handling without an ophthalmologist
In just 30 seconds
Optimizing consultation times
Benefits for patients and professionals
Complies with the European Community Class IIa according to the Medical Device Directive 93/42 / EEC.
Professionals
Increased patient traffic, optimizing the consultation time, with easy handling without an ophthalmologist
More information »
Benefits
Allows the detection of retinopathy and maculopathy in early stage for treatment, no waiting, no discomfort and at a low cost.
More information »